secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001193125-23-256912
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies appoints Virginie Boucinha as CFO replacing Sébastien Robitaille
--------------------------------------------------------------------------------

- Virginie Boucinha appointed CFO effective Nov 6, 2023; reports to CEO Daniel Tassé.
- Sébastien Robitaille departs on Nov 17, 2023 to pursue other opportunities; two-week transition.
- Boucinha brings ~30 years pharma experience, most recently Group Performance Director at Pierre Fabre.
- Prior roles at Sanofi include Chief of Staff to CEO and Global Transformation Office Head.
- Company advancing two BLAs for Viaskin in toddlers and children with peanut allergy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523256912/0001193125-23-256912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523256912/d533486d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-256912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer